文献速递冠心病

既往心梗且 LVEF≥40% 的稳定患者停用 β 受体阻滞剂的个体数据汇总分析

Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data.
PubMed 文献 · Lancet · 2026-08-30

该研究汇总 ABYSS 与 SMART-DECISION 两项随机试验的个体数据,纳入心梗后超过 6 个月、LVEF≥40% 且无心力衰竭的稳定患者 6238 例。比较停用与继续使用 β 受体阻滞剂,主要终点为全因死亡、心梗、卒中或心血管原因住院的复合终点。

要点

  • 既往心梗、LVEF≥40%、无心力衰竭且无其他适应证的稳定患者可考虑停用 β 受体阻滞剂。
  • 主要复合终点达到非劣效,但结果受住院事件构成和试验差异影响。

核心结论

  • 在既往心梗、LVEF≥40%、无心力衰竭且无其他 β 受体阻滞剂适应证的稳定患者中,停药在主要终点和关键次要终点均达到非劣效标准。

研究设计与样本

  • 对 ABYSS 和 SMART-DECISION 两项随机试验的个体患者数据进行汇总分析,共纳入 6238 例患者,停药组 3092 例,继续组 3146 例。

主要发现

  • 结果在不同基础 LVEF 水平下保持一致。

关键数值与推荐

  • 入组标准为心梗后超过 6 个月、LVEF≥40%、无心力衰竭的稳定患者。
  • 主要复合终点包括全因死亡、心肌梗死、卒中或心血管原因住院。
  • 关键次要复合终点包括全因死亡、心肌梗死或心力衰竭住院。

临床怎么用

  • 对于既往心梗超过 6 个月、LVEF≥40%、无心力衰竭且无其他 β 受体阻滞剂明确适应证的稳定患者,停用 β 受体阻滞剂可作为一种合理选择。
  • 临床决策应结合患者其他合并适应证、药物耐受性和个体风险评估。

局限性

  • 主要终点的解读受到其构成以住院事件为主以及各试验间构成差异的限制。
  • 非劣效界值设置的临床可接受性需结合具体临床情境判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many stable patients with chronic coronary syndrome continue β-blocker therapy for years after a myocardial infarction, despite having no clear ongoing indication. Whether β-blockers can be safely discontinued in such patients remains uncertain. The objective of this analysis was to assess the non-inferiority of β-blocker discontinuation versus continuation in patients with previous myocardial infarction and no remaining indication. METHODS: We performed a pooled analysis of individual patient data from the ABYSS and SMART-DECISION randomised trials in stable patients over 6 months after a myocardial infarction with a left ventricular ejection fraction of ≥40% and no heart failure. Non-inferiority was assessed for the composite primary endpoint of all-cause death, myocardial infarction, stroke, or hospitalisation for cardiovascular reasons, and for the key secondary endpoint of all-cause death, myocardial infarction, or hospitalisation for heart failure. Analyses used a one-stage mixed-effects Cox proportional hazards model including trial as a random effect with margins of 1·25 for the primary endpoint and 1·40 for the key secondary endpoint. The review protocol was registered with PROSPERO, number CRD420261299839. FINDINGS: Among 6238 patients (3698 from ABYSS and 2540 from SMART-DECISION), 3092 were assigned to β-blocker discontinuation and 3146 to continuation. Median time from index myocardial infarction to randomisation was 3·6 years (IQR 1·6-7·5) and median follow-up was 3·0 years (2·3-3·8). The primary endpoint occurred in 532 (17·2%) of 3092 patients in the β-blocker discontinuation group and 500 (15·9%) of 3146 in the continuation group (hazard ratio 1·09 [95% CI 0·97-1·24]; pnon-inferiority=0·016). The key secondary endpoint occurred in 201 (6·5%) of 3092 patients in the discontinuation group and 201 (6·4%) of 3146 patients in the continuation group (1·01 [0·83-1·23]; pnon-inferiority=0·0006). Findings were consistent irrespective of background left ventricular ejection fraction. INTERPRETATION: In stable patients with previous myocardial infarction, left ventricular ejection fraction ≥40%, no heart failure, and no other indication for β-blocker therapy, discontinuation met the non-inferiority criteria for the primary and key secondary endpoints. Interpretation of the primary endpoint is limited by its hospitalisation-heavy and trial-dependent composition. FUNDING: None.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Silvain, Choi, Monguillon, et al. Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data. Lancet. 2026. PMID: 42669300. doi:10.1016/S0140-6736(26)01426-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。